Zusammenfassung
Obwohl die Einführung von Infliximab die Behandlung des M. Crohn revolutioniert hat, haben die gängigen Immunsuppressiva weiterhin ihre Bedeutung. Vor allem die Remissionserhaltung stellt, wie auch der steroidrefraktäre Verlauf, eine spezielle Anforderung an die Pharmakotherapie dar. Hier haben Azathioprin und 6-Mercaptopurin und in geringerem Ausmaß auch Methotrexat ihren Stellenwert (Pearson et al. 1995; Sandborn 1996). Cyclopsorin A hat sich in der Akutbehandlung steroidrefraktärer Verläufe der Colitis ulcerosa bewährt, wobei eine langfristige Remission allerdings nur in der Hälfte der Fälle aufrecht erhalten werden kann (Carbonnel et al. 1996; Hyde et al. 1998; Lichtiger et al. 1994). Für Cyclosporin A bei M. Crohn liegen keine überzeugenden Studienergebnisse vor (Brynskov et al. 1991; Feagan et al. 1994; Jewell et al. 1994; Stange et al. 1995).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bousvaros A, Kirschner B, Werlin S et al. (1997) Oral tacrolimus treatment of severe colitis in children. Gastroenterology 112: A941
Bousvaros A, Wang A, Leichtner AM (1996) Tacrolimus (FK-506) treatment of fulminant colitis in a child. J Pediatr Gastroenterol Nutr 23: 329–333
Brynskov J, Freund L, Rasmussen SN et al. (1991) Final report on a placebo-controlled, double blind, randomised, multicentre trial of cyclosporine treatment in active chronic Crohn’s disease. Scand J Gastroenterol 26: 689–695
Carbonnel F, Boruchowicz A, Duelos B et al. (1996) Intravenous cyclosporine in attacks of ulcerative colitis. Dig Dis Sci 41: 2471–2476
European FK506 Multicentre Liver Study Group (1994) Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 344: 423–428
European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345: 1321–1325
Feagan BG, McDonald J WD, Rochon J (1994) Low-dose cyclosporine for the treatment of Crohn’s disease. N Engl J Med 330: 1846–1851
Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF (1998) Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus. Am J Gastroenterol 93: 1860–1866
Fellermann K, Steffen M, Stein J et al. (2000) Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 14: 171–176
Fickert P, Hinterleitner TA, Wenzl HH, Aichbichler BW, Petritsch W (1998) Mycophenolate mofetil in patients with Crohn’s disease. Am J Gastroenterol 93: 2529–2532
Florin TH, Roberts RK, Watson MR, Radford-Smith GL (1998) Treatment of steroid refractory inflammatory bowel disease ( IBD) with mycophenolate mofetil. Aust N Z J Med 28: 344–345
Hassard P, Vasilauskas E, Kam L, Targan S, Abreu-Martin MT (1999) Limited benefit of mycophenolate mofetil (MMF) for the treatment of severe refractory Crohn’s disease ( CD ). Gastroenterology 116: A550
Horgan K (1997) Initial experience with mycophenolate mofetil in the treatment of severe inflammatory bowel disease. Gastroenterology 112: A999
Hyde GM, Thillainayagam AV, Jewell DP (1998) Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal Eur J Gastroenterol Hepatol 10: 411–413
Jewell DP, Lennard-Jones JE and the Cyclosporin Study Group of Great Britain and Ireland (1994) Oral cyclosporin for chronic active Crohn’s disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 6: 499–505
Lichtiger S, Present DH, Kornbluth A et al. (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330: 1841–1845
Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ (1999) Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn’s disease perianal fistulae. Inflam Bow Dis 5: 239–245
Nehme OS, Overley CA, O’Brien JJ (1998) The role of mycophenolate mofetil in the management of refractory inflammatory bowel disease ( IBD ). Gastroenterology 114: A1049
Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Büschenfelde K-H, Schlaak JF (1999) Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 44: 625–628
Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn’s disease. A meta-analysis. Ann Intern Med 123: 132–142
Sandborn WJ (1996) A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 91: 423–433
Sandborn WJ (1997) Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn’s disease. Am J Gastroenterol 92: 876–879
Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplant 60: 225–232
Stange EF, Modigliani R, Penna AS (1995) European trial of cyclosporin in chronic active Crohn’s disease: a 12 month study. Gastroenterology 109: 774–782
Strand V, Cohen S, Schiff M et al. (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159: 2542–2550
The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplant 61: 1029–1037
The U.S. Multicenter FK506 Liver Study Group (1994) A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331: 1110–1115
Woodle ES, Thistlethwaite JR, Gordon JH et al. (1996) A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplant 62: 594–599
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Witthöft, T., Fellermann, K. (2001). Einsatz neuer Immunsuppressiva. In: Dignass, A., Stein, J. (eds) Chronisch entzündliche Darmerkrankungen. Gastroenterologie Update, vol 2000. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59556-1_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-59556-1_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-67722-2
Online ISBN: 978-3-642-59556-1
eBook Packages: Springer Book Archive